Cystic Fibrosis Transmembrane Conductance Regulator Inhibits Epithelial Na+ Channels Carrying Liddle's Syndrome Mutations*

Anna Hopf, Rainer Schreiber, Marcus Mall, Rainer Greger, and Karl KunzelmannDagger

From the Physiologisches Institut, Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Straße 7, 79104 Freiburg, Germany

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Epithelial Na+ channels (ENaC) are inhibited by the cystic fibrosis transmembrane conductance regulator (CFTR) upon activation by protein kinase A. It is, however, still unclear how CFTR regulates the activity of ENaC. In the present study we examined whether CFTR interacts with ENaC by interfering with the Nedd4- and ubiquitin-mediated endocytosis of ENaC. Various C-terminal mutations were introduced into the three alpha -, beta -, and gamma -subunits of the rat epithelial Na+ channel, thereby eliminating PY motifs, which are important binding domains for the ubiquitin ligase Nedd4. When expressed in Xenopus oocytes, most of the ENaC stop (alpha -H647X, beta -P565X, gamma -S608X) or point (alpha -P671A, beta -Y618A, gamma -P(624-626)A) mutations induced enhanced Na+ currents when compared with wild type alpha ,beta ,gamma -rENaC. However, ENaC currents formed by either of the mutant alpha -, beta -, or gamma -subunits were inhibited during activation of CFTR by forskolin (10 µmol/l) and 3-isobutyl-1-methylxanthine (1 mmol/l). Antibodies to dynamin or ubiquitin enhanced alpha ,beta ,gamma -rENaC whole cell Na+ conductance but did not interfere with inhibition of ENaC by CFTR. Another mutant, beta -T592M,T593A-ENaC, also showed enhanced Na+ currents, which were down-regulated by CFTR. Moreover, activation of ENaC by extracellular proteases and xCAP1 does not disturb CFTR-dependent inhibition of ENaC. We conclude that regulation of ENaC by CFTR is distal to other regulatory limbs and does not involve Nedd4-dependent ubiquitination.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recent studies have indicated that epithelial Na+ channels (ENaC)1 are inhibited during activation of Cl- secretion in human airways and the colonic epithelium (1).2 These tissues coexpress both CFTR and alpha ,beta ,gamma -rENaC and demonstrate that CFTR, when activated by cAMP, inhibits epithelial Na+ channels. In fact, recent studies in cells expressing both recombinant CFTR and ENaC indicate CFTR-dependent inhibition of ENaC (3, 4). Currently, several models for regulation may be proposed: (i) we have shown recently that CFTR and alpha ,beta ,gamma -rENaC may interact directly (5). Two independent groups detected inhibition of ENaC single channel currents by CFTR in isolated membranes (6, 7), while other studies demonstrate inhibition of ENaC by increase of cytosolic Cl- activities (8, 9). The results of the latter study are supported by the notion that Cl- movement through the activated CFTR Cl- channel is essential for the inhibition of ENaC (10). Very recently, a C-terminal CFTR domain was detected that binds to PDZ domains of proteins that anchor CFTR to the cytoskeleton (11, 12). This could provide a potential mechanism through which CFTR can affect the activity of other membrane proteins. Along this line, the cytoskeleton has been suggested for a long time to participate in the regulation of the epithelial Na+ channel (13).

Nedd4-dependent ubiquitination turned out to be an important regulatory pathway for ENaC that is also of clinical relevance in Liddle's disease (14-16). Regulation by Nedd4 includes binding of Nedd4 to a PY motif in the C terminus of all three ENaC subunits via WW domain interaction with subsequent ubiquitination- and dynamin-mediated endocytosis of ENaC (17-19). In the present paper we addressed the question to what extent the PY motifs in the three rENaC subunits contribute to the CFTR-dependent regulation of rENaC and whether elimination of respective motifs interferes with the ability of CFTR to down-regulate rENaC. This seems to be of particular importance since Liddle's disease patients do not suffer from pulmonary symptoms that would be caused by an enhanced Na+ conductance in the airways along with hyperabsorption of the airway surface fluid. In addition, preliminary results demonstrate inhibition of alpha ,beta ,gamma 573X-ENaC by CFTR in Madin-Darby canine kidney cells (20). In this study we coexpressed various ENaC mutants that show a gain of function. We examined the inhibitory effects of CFTR on these ENaC mutants. In addition, we analyzed whether another, recently identified regulatory pathway for ENaC, the epithelial serine protease CAP1 (21), interferes with CFTR-dependent inhibition of ENaC.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Liddle and beta T592M,T593A Mutations-- Mutations of the rat epithelial Na+ channel subunits were generated by polymerase chain reaction. For the C-terminal stop mutations alpha -H647X, beta -P565X, gamma -S608X the following sense (s) and antisense (as) oligonucleotides (5'-3') were used: alpha -H647X, CGACCCACGCGTCGCG (s); AGGACAGAAACGGGACG (as); beta -P565X, CCCACGCGTCCGACC (s), GCCGCCTCCTGCGCA (as); gamma -S608X, TCGACCCACGCGTCC (s), AGGTAAAAGTGGGCAGGTC (as). C-terminal point mutations alpha -P671A, beta -Y618A, gamma -P (624-626)A were generated using GACAGCCCCTCCAGCTGCCTATGCTACT (s), AGTAGCATAGCCAGCTGGAGGG-GCTGTC (as) for alpha -P671A); GCACTCCACCTCCCAATGCGCACTCCCTGAGGCTG (s), CAGCCTCAGGGAGTGGCGATTGGGAGGTGGAGTGC (as) for beta -Y618A; GGTGCCTGGCACAGCGGCCGCCAGATACAATA (s), TATTGTATCTGGCGGCCGCTGTGCCTGGTATT (as) for gamma -P (624-626)A). beta T592M,T593A was created using the oligonucleotides TCTTCCAGCCTGACATGGCTAGCTGCAGGCCCAAT (s), ATTGGGCCTGCAGCTAGCCATGTCAGGCTGGAA (as). ENaC mutations were checked for correct sequences by restriction digest and by cycle sequencing (PRISM, Perkin-Elmer). cDNAs encoding alpha ,beta ,gamma -rENaC and the serine protease xCAP1 were kindly provided by Prof. Dr. B. Rossier, Pharmacological Institute of Lausanne, Switzerland.

cRNAs for CFTR, wt, and Mutant Epithelial Na+ Channel (rENaC) Subunits and xCAP1-- cDNAs encoding wild type human CFTR, the three (alpha , beta , gamma ) subunits of the rat amiloride-inhibitable Na+ channel ENaC, and the Xenopus protease xCAP1 were linearized using either NotI or KpnI, and cRNA was in vitro transcribed using T7, T3, or SP6 polymerases and a 5'-cap (mCAP mRNA capping kit, Stratagene).

Preparation of Oocytes and Microinjection of cRNA-- Isolation and microinjection of oocytes have been described in a previous report (10). In brief, after isolation from adult Xenopus laevis female frogs oocytes were dispersed and defolliculated by a 0.5-h treatment with collagenase (type A, Boehringer, Mannheim, Germany). Subsequently oocytes were rinsed and kept in ND96 buffer (in mmol/l): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 2.5 sodium pyruvate, pH 7.55, supplemented with theophylline (0.5 mmol/l) and gentamycin (5 mg/l) at 18 °C. Oocytes of identical batches were injected with cRNA of either wt or mutant alpha ,beta ,gamma -rENaC (each subunit 10 ng), xCAP1, and CFTR (each 20 ng), respectively, after dissolving cRNAs in about 50 nl of double-distilled water (PV830 pneumatic pico pump, WPI, Berlin, Germany). Oocytes injected with 50 nl of double-distilled water served as controls. For some experimental protocols oocytes were injected with 50 ng of either sense or antisense oligonucleotides of the serine protease xCAP1 (21).

Electrophysiological Analysis of Xenopus Oocytes-- 2-4 days after injection oocytes were impaled with two electrodes (Clark instruments), which had resistances of 1 MOmega when filled with 2.7 mol/l KCl. A flowing (2.7 mol/l) KCl electrode served as bath reference. Membrane currents were measured by voltage clamping of the oocytes (OOC-1 amplifier, WPI) in intervals from -90 to +30 mV in steps of 10 mV. Current data were filtered at 400 Hz (OOC-1 amplifier). Between intervals, oocytes were voltage-clamped to their spontaneous membrane voltage for 20 s. Data were collected continuously on a computer hard disc and analyzed by using the programs chart and scope (McLab, AD-Instruments, Macintosh). Conductances were calculated for the voltage clamp range of -90 to +30 mV according to Ohm's law. During the whole experiment the bath was continuously perfused at a rate of 5-10 ml/min.

Materials and t Test-- All used compounds were of highest available grade of purity. 3-Isobutyl-1-methylxanthine (IBMX), forskolin, trypsin, and amiloride were all from Sigma (Deisenhofen, Germany). The dynamin and ubiquitin antibodies were purchased from Calbiochem (Bad Soden, Germany) and Dianova (Hamburg, Germany). Sense and antisense oligonucleotides of the protease xCAP1 were synthesized by the facility of the local University and were stabilized by phosphorothioate modification. The oligonucleotides had the following (5'-3') sequence: ATGGAGCCTCTTCCACTTCTC (sense) and GAGAAGTGGAAGTGGCTCCAT (antisense). Statistical analysis was performed according to Student's t test. p values <0.05 were accepted to indicate statistical significance. All experiments were conducted at room temperature (22 °C).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Effects of Deletion of C-terminal PY Motifs in alpha ,beta ,gamma -rENaC-- PY motifs in either alpha -, beta -, or gamma -subunits of rENaC were deleted by either C-terminal point (alpha -P671A, beta -Y618A, gamma -P(624-626)A) or C-terminal stop mutations (alpha -H647X, beta -P565X, gamma -S608X). A representative record of the whole cell current from an oocyte coexpressing beta -P565X with wild type alpha - and gamma -subunits is shown in the lower trace of Fig. 1. This current is enhanced when compared with that induced by alpha ,beta ,gamma -rENaC (Fig. 1, upper trace). Amiloride-sensitive whole cell conductances (GENaC-mut) were calculated for the various mutations and were compared with that of alpha ,beta ,gamma -rENaC (GENaC-mut/GENaC-wt). As demonstrated in Fig. 2 GENaC was significantly enhanced for beta -P565X, gamma -S608X, alpha -P671A, and beta -Y618A, while alpha -H647X and gamma -P(624-626)A did not produce enhanced conductances. These results confirm those of previous studies (17, 22) and indicate the importance of the C-terminal PY motif for the regulation of ENaC.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Representative examples of whole cell currents and inhibition by amiloride (10 µmol/l) observed in oocytes expressing alpha ,beta ,gamma -rENaC (upper trace) or alpha ,beta -P565X,gamma -rENaC (lower trace). Oocytes were voltage-clamped in steps of 10 mV (for 1 s) from -90 mV to +30 mV.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of C-terminal deletions and elimination of PY motifs in alpha -, beta -, and gamma -subunits of ENaC on amiloride-sensitive Na+ currents. cRNAs encoding either of the alpha -, beta -, or gamma -mutants were coinjected with the complementary wild type subunits. The corresponding bars indicate whole cell conductances normalized for wild type ENaC values (GENaC-mut/GENaC-wt). Results are means ± S.E. (number of experiments). * indicates significant difference from Gwt.

ENaC Carrying Liddle Mutations Are Inhibited by CFTR-- Individual ENaC mutants were coexpressed together with CFTR, and we examined whether these ENaC Liddle mutants are still down-regulated by CFTR. As demonstrated in Fig. 3A, the whole cell conductance that is produced by alpha ,beta ,gamma -rENaC and is inhibited by 10 µmol/l amiloride (A) is attenuated after stimulation of CFTR by IBMX (1 mmol/l) and forskolin (10 µmol/l). The summary (Fig. 3C) indicates significant inhibition of alpha ,beta ,gamma -rENaC by CFTR, while no effects of IBMX and forskolin could be detected in the absence of CFTR. Similar to alpha ,beta ,gamma -rENaC, also alpha ,beta ,gamma -S608X-rENaC whole cell conductances were down-regulated upon stimulation of CFTR with IBMX and forskolin (Fig. 3B). The results from the various ENaC mutants coexpressed with CFTR are summarized in Fig. 4. It is shown that GENaC caused by each of the C-terminal stop (A) or point (B) mutants is significantly attenuated upon stimulation of CFTR by IBMX and forskolin (black bars). We, therefore, conclude that PY motifs do not participate in CFTR-dependent regulation of ENaC.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of alpha ,beta ,gamma -rENaC (A) and alpha ,beta ,gamma S608X-rENaC (B) by CFTR. Whole cell conductances were blocked reversibly by amiloride (A, 10 µmol/l). The effects of amiloride on both wt alpha ,beta ,gamma -rENaC and alpha ,beta ,gamma S608X-rENaC were attenuated after activation of a CFTR Cl- conductance by IBMX (1 mmol/l) and forskolin (IBMX/Fors, 10 µmol/l). C, summary of the amiloride-sensitive Na+ conductance (GENaC) in Xenopus oocytes expressing alpha ,beta ,gamma -rENaC or coexpressing alpha ,beta ,gamma -rENaC together with CFTR. Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride. # indicates significant down-regulation of ENaC by CFTR.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   CFTR-dependent inhibition of ENaC carrying C-terminal deletions (A, B) or point mutations (A, C) in either alpha -, beta -, or gamma -subunits of rENaC. A, continuous recording of the whole cell conductances produced by either point or stop mutations of ENaC and effect of amiloride before and after activation of CFTR. Summary of GENaC produced by ENaC carrying either stop (B) or point (C) mutations before (white bars) and after (black bars) stimulation with IBMX and forskolin (IBMX/Fors). Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride. # indicates significant inhibition of ENaC by CFTR.

Antibodies for Ubiquitin and Dynamin Enhanced ENaC Conductance and Do Not Interfere with the Inhibition by CFTR-- In order to further examine the role of the Nedd4/ubiquitin cascade in the regulation of ENaC by CFTR, we made use of two different antibodies, which bind to either ubiquitin and dynamin. When coinjected with ENaC, both of these antibodies enhanced GENaC when compared with amiloride-sensitive whole cell conductances measured in oocytes from the same batch and injected solely with alpha ,beta ,gamma -rENaC (Fig. 5A). In another series of experiments, we coinjected alpha ,beta ,gamma -rENaC together with CFTR and ubiquitin or dynamin antibodies. The summary of these experiments indicates that even after interfering with both intracellular ubiquitin and dynamin, CFTR is able to inhibit ENaC (Fig. 5B).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   A, effects of dynamin and ubiquitin antibodies, respectively, on GENaC. Oocytes injected with ENaC and equal amounts of water (H2O) served as controls. # indicates significantly enhanced GENaC in coinjected oocytes compared with oocytes injected with ENaC only. B, summary of GENaC in Xenopus oocytes coinjected with CFTR and dynamin or ubiquitin antibodies. GENaC is shown before (white bars) and after (black bars) activation of CFTR by IBMX (1 mmol/l) and forskolin (IBMX/Fors, 10 µmol/l). Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride. # indicates significant inhibition of ENaC by CFTR.

CFTR-dependent Inhibition of beta T592M,T593A-ENaC-- According to previous reports, a mutation in the beta -subunit of the human ENaC (beta -T594M) causes a loss of protein kinase C inhibition and leads to salt-sensitive hypertension in the African-American population (23). We examined whether the respective mutations in the rat ENaC beta -subunit interferes with CFTR-dependent inhibition. beta T592M,T593A-rENaC, when coexpressed with equal amounts of alpha - and gamma -subunits, led to an amiloride sensitive Na+ conductance that was significantly higher than in oocytes from the same batch injected with wt alpha ,beta ,gamma -ENaC (Fig. 6B). Stimulation with IBMX and forskolin had no effect on alpha ,beta T592M,T593A,gamma -rENaC Na+ conductance (13.7 ± 1.2 versus 13.5 ± 1.9 microsiemens; n = 4). When coexpressed with CFTR, alpha ,beta T592M,T593A,gamma -rENaC conductance was significantly attenuated by stimulation with IBMX and forskolin (Fig. 6, A and C). Thus, gain of function mutations of ENaC do not limit inhibition of ENaC by CFTR.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   CFTR-dependent inhibition of the ENaC mutant beta T593A/T594M. A, continuous recording of the whole cell conductance and effect of amiloride before and after activation of CFTR. B, summary of GENaC produced by wild type alpha ,beta ,gamma -ENaC or alpha ,beta -T593A/594M,gamma -ENaC. C, summary of GENaC produced by alpha ,beta -T593A/594M,gamma -ENaC before (white bar) and after (black bar) stimulation with IBMX and forskolin (IBMX/Fors). Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride. § indicates significantly enhanced ENaC conductance when compared with wt ENaC. # indicates significant inhibition of ENaC by CFTR.

ENaC Conductance Activated by Extracellular Trypsin Is Inhibited by CFTR-- It was shown recently that extracellular proteases activate ENaC probably by interfering with the extracellular loop of ENaC (21). We also found augmentation of GENaC by trypsin in a dose-dependent manner (Fig. 7B). In an oocyte coexpressing both ENaC and CFTR the amiloride-sensitive Na+ conductance was enhanced after exposure to 2 µg/ml trypsin (Fig. 7A). Upon stimulation by IBMX (1 mmol/l) and forskolin (10 µmol/l) and activation of a CFTR whole cell conductance, the inhibitory effect of amiloride was largely attenuated. The summary shown in Fig. 7C indicates a significant increase of GENaC by trypsin and inhibition of GENaC by CFTR. The results demonstrate the ability of CFTR to inhibit ENaC in the presence of extracellular protease activity and suggest that the portion of GENaC that is activated by trypsin is also subjected to down-regulation by CFTR.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   A, activation of alpha ,beta ,gamma -rENaC by trypsin (2 µg/ml) and inhibition of alpha ,beta ,gamma -rENaC by CFTR. Whole cell conductances were blocked reversibly by amiloride (A, 10 µmol/l). The effect of amiloride was augmented after application of trypsin and was attenuated after activation of a CFTR Cl- conductance by IBMX (1 mmol/l) and forskolin (IBMX/Fors, 10 µmol/l) in the continuous presence of trypsin. B, concentration-response curve for the effects of trypsin on GENaC. C, summary of GENaC coexpressed with CFTR. Effect of incubation with trypsin and activation of CFTR by IBMX and forskolin (IBMX/F) is shown. Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride. ° indicates significant difference from control. # indicates significant inhibition of ENaC by CFTR.

Inhibtion of ENaC by CFTR in the Presence or Absence of the Epithelial Protease xCAP1-- In order to investigate the impact of the serine protease xCAP1, we blocked expression of xCAP1 by injection of xCAP1 antisense oligonucleotides. The summary of the results is shown in Fig. 8, A and B, and demonstrate attenuation of GENaC in oocytes coinjected with CFTR/ENaC/xCAP1 antisense compared with oocytes coinjected with CFTR/ENaC/xCAP1 sense. However, when CFTR was activated by IBMX and forskolin, GENaC was inhibited in both sense- and antisense-injected oocytes. In a second approach we overexpressed xCAP1 together with ENaC and xCAP1 together with ENaC and CFTR. The summary of the results from these experiments is shown in Fig. 8C. The data demonstrate that GENaC was approximately doubled when ENaC was coexpressed with xCAP1. However, a smaller GENaC value was detected when CFTR was coexpressed with both rENaC and xCAP1. It is shown that in the presence of xCAP1, CFTR was still able to down-regulate ENaC. We conclude that larger ENaC currents that are detected in the presence of protease activity are inhibited by CFTR.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of xCAP1 sense (A) and xCAP1 antisense (B) oligonucleotides on the expression of GENaC inhibition by CFTR. # indicates significantly attenuated GENaC in antisense compared with sense-injected oocytes. ° indicates significant inhibition of ENaC by CFTR. Black bars show GENaC when CFTR was activated by IBMX and forskolin (IBMX/F). C, GENaC in oocytes injected with alpha ,beta ,gamma -rENaC only or coinjected with alpha ,beta ,gamma -rENaC and xCAP1. ° indicates significantly enhanced GENaC in coinjected ooyctes. GENaC was lower in oocytes coexpressing alpha ,beta ,gamma -rENaC, xCAP1, and CFTR and was significantly (#) inhibited after activation of CFTR by IBMX and forskolin (IBMX/Fors). Results are means ± S.E. (number of experiments). * indicates significant effects of amiloride.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The amplitude of the epithelial Na+ current is determined by the number of ENaC channels present in the cell membrane and by the activity of membrane resident channels (18, 19, 22). Correspondingly, dual effects of Liddle's mutation on Po and the number of Na+ channels expressed at the cell surface have been described (19). However, endocytosis of ENaC by a Nedd4/ubiquitin/dynamin-dependent pathway is probably the predominant mechanism for regulation of epithelial Na+ absorption (14). Thus, a loss of Nedd4 recognition site causes enhanced Na+ absorption in kidney collecting ducts and a salt-sensitive hypertension (15-17). The well known Na+ feedback (24) detected in mouse mandibular duct cells occurs via activation of G0 proteins through increase of intracellular Na+ and probably also via Nedd4-dependent retrieval of Na+ channels from the cell membrane (25). However, in Xenopus oocytes inhibition of ENaC channels by Na+ occurs without changing the number of ENaC channels (2, 19).

Because Nedd4 and ubiquitination play such a central role in ENaC regulation, we examined whether down-regulation of ENaC by CFTR occurs via this regulatory axis. According to the present results, however, this seems rather unlikely, since ENaC channels containing either alpha -, beta -, or gamma -subunits with defective PY motifs were inhibited during activation of CFTR. Moreover, the data indicate strong inhibition by CFTR for most of the ENaC mutants, which may suggest that the additional portion of Na+ conductance that is due to limited retrieval from the cell membrane and enhanced ENaC activity is also inhibited by CFTR. Similar holds true for beta T592M,T593A-ENaC and ENaC currents activated by proteases. We may therefore assume that CFTR-dependent inhibition of ENaC is superior to the regulation by the ubiquitin-dependent pathway and extracellular proteases, including xCAP1. This also applies to other gain of function mutations like beta T592M,T593A-rENaC, which was not regulated directly by cAMP in our hands (23). The results of the present report also explain why Liddle's disease patients, unlike CF patients, do not show enhanced Na+ conductance in their airways and therefore do not suffer from pulmonary symptoms (20).

Nedd4/ubiquitin-dependent regulation of ENaC does not provide a mechanism through which ENaC is regulated by CFTR. The relatively fast onset and reversibility of the inhibitory effects of CFTR on ENaC (10) are in good agreement with such a result. The question regarding the mechanisms underlying the CFTR-dependent regulation of ENaC can therefore not completely be answered at the moment. We know from previous reports that interaction of CFTR with ENaC takes place even in isolated membranes and after reconstitution into planar lipid bilayers (6, 7). The interaction does not require full-length CFTR but only cytosolic domains of CFTR (5) and largely depends on CFTR's ability to conduct Cl- ions (10). Additional studies are needed to show whether the recently identified PDZ domain interaction enables functional coupling of CFTR and ENaC.

    ACKNOWLEDGEMENTS

We gratefully acknowledge the expert technical assistance of H. Schauer.

    FOOTNOTES

* This work was supported by Deutsche Forschungsgemeinschaft Grant Ku756/2-3, Zentrum klinische Forschung 1 (ZKF1), and Fritz Thyssen Stiftung Grant 1996/1044.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a Heisenberg fellowship. To whom correspondence should be addressed. Tel.: 49-761-203-5153; Fax: 49-761-203-5191; E-mail: kkunzel{at}sibm2.ruf.uni-freiburg.de.

2 M. Mall, M. Bleich, J. Kühr, M. Brandis, R. Greger, and K. Kunzelmann, submitted for publication.

    ABBREVIATIONS

The abbreviations used are: ENaC, epithelial Na+ channel(s); CFTR, cystic fibrosis transmembrane conductance regulator; wt, wild type; l, liter; IBMX, 3-isobutyl-1-methylxanthine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Mall, M., Bleich, M., Greger, R., Schreiber, R., and Kunzelmann, K. (1998) J. Clin. Invest. 102, 15-21[Abstract/Free Full Text]
  2. Kellenberger, S., Gautschi, I., Rossier, B. C., and Schild, L. (1998) J. Clin. Invest. 101, 2741-2750[Abstract/Free Full Text]
  3. Stutts, M. J., Canessa, C. M., Olsen, J. C., Hamrick, M., Cohn, J. A., Rossier, B. C., and Boucher, R. C. (1995) Science 269, 847-850[Medline] [Order article via Infotrieve]
  4. Mall, M., Hipper, A., Greger, R., and Kunzelmann, K. (1996) FEBS Lett. 381, 47-52[CrossRef][Medline] [Order article via Infotrieve]
  5. Kunzelmann, K., Kiser, G., Schreiber, R., and Riordan, J. R. (1997) FEBS Lett. 400, 341-344[CrossRef][Medline] [Order article via Infotrieve]
  6. Stutts, M. J., Rossier, B. C., and Boucher, R. C. (1997) J. Biol. Chem. 272, 14037-14040[Abstract/Free Full Text]
  7. Ismailov, I. I., Awayda, M. S., Jovov, B., Berdiev, B. K., Fuller, C. M., Dedman, J. R., Kaetzel, M. A., and Benos, D. J. (1996) J. Biol. Chem. 271, 4725-4732[Abstract/Free Full Text]
  8. Dinudom, A., Young, J. A., and Cook, D. I. (1993) J. Membr. Biol. 135, 289-295[Medline] [Order article via Infotrieve]
  9. Komwatana, P., Dinudom, A., Young, J. A., and Cook, D. I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8107-8111[Abstract/Free Full Text]
  10. Briel, M., Greger, R., and Kunzelmann, K. (1998) J. Physiol. (Lond.) 508, 825-836[Abstract/Free Full Text]
  11. Short, D. B., Trotter, K. W., Reczek, D., Kreda, S. M., Bretscher, A., Boucher, R. C., Stutts, M. J., and Milgram, S. L. (1998) J. Biol. Chem. 273, 19797-19801[Abstract/Free Full Text]
  12. Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B., and Li, M. (1998) FEBS Lett. 427, 103-108[CrossRef][Medline] [Order article via Infotrieve]
  13. Ismailov, I. I., Berdiev, B. K., Shlyonsky, V. G., Fuller, C. M., Prat, A. G., Jovov, B., Cantiello, H. F., Ausiello, D. A., and Benos, D. J. (1997) Am. J. Physiol. 272, C1077-C1086[Abstract/Free Full Text]
  14. Staub, O., Gautschi, I., Ishikawa, T., Breitschopf, K., Ciechanover, A., Schild, L., and Rotin, D. (1997) EMBO. J. 16, 6325-6336[Abstract/Free Full Text]
  15. Hansson, J. H., Nelson-Williams, C., Suzuki, H., Schild, L., Shimkets, R., Lu, Y., Canessa, C., Iwasaki, T., Rossier, B., and Lifton, R. P. (1995) Nat. Genet. 11, 76-82[Medline] [Order article via Infotrieve]
  16. Shimkets, R. A., Warnock, D. G., Bositis, C. M., Nelson-Williams, C., Hansson, J. H., Schambelan, M., Gill, J. R., Jr., Ulick, S., Milora, R. V., and Findling, J. W. (1994) Cell 79, 407-414[Medline] [Order article via Infotrieve]
  17. Schild, L., Lu, Y., Gautschi, I., Schneeberger, E., Lifton, R. P., and Rossier, B. C. (1996) EMBO. J. 15, 2381-2387[Abstract]
  18. Shimkets, R. A., Lifton, R. P., and Canessa, C. M. (1997) J. Biol. Chem. 272, 25537-25541[Abstract/Free Full Text]
  19. Firsov, D., Schild, L., Gautschi, I., Merillat, A. M., Schneeberger, E., and Rossier, B. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15370-15375[Abstract/Free Full Text]
  20. Stutts, M. J., Homolya, V., Robinson, J., Zhou, J., Boucher, R. C., and Knowles, M. R. (1998) Pediatr. Pulmonol. Suppl. 17, 217 (abstr.)
  21. Vallet, V., Chraibi, A., Gaeggeler, H. P., Horisberger, J. D., and Rossier, B. C. (1997) Nature 389, 607-610[CrossRef][Medline] [Order article via Infotrieve]
  22. Snyder, P. M., Price, M. P., McDonald, F. J., Adams, C. M., Volk, K. A., Zeiher, B. G., Stokes, J. B., and Welsh, M. J. (1995) Cell 83, 969-978[Medline] [Order article via Infotrieve]
  23. Cui, Y., Su, Y. R., Rutkowski, M., Reif, M., Menon, A. G., and Pun, R. Y. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9962-9966[Abstract/Free Full Text]
  24. Garty, H., and Palmer, L. G. (1997) Physiol. Rev. 77, 359-396[Abstract/Free Full Text]
  25. Dinudom, A., Harvey, K. F., Komwatana, P., Young, J. A., Kumar, S., and Cook, D. I. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7169-7173[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.